
On January 16, 2026, within the framework of the Annual Scientific Conference 2026 organized by Vietnam–Russia International Eye Hospital, Ho Chi Minh City, many in-depth professional topics in the field of ophthalmology were presented and discussed.

Among them, Phakic ICL EVO was one of the topics that attracted significant attention, with reports based on real-world treatment data at the hospital.
The data shared at the conference showed:
- Each year, the hospital performs approximately 650–750 refractive surgeries
- The total number of cases performed to date is nearly 3,000
- Phakic ICL EVO accounts for more than 80% of treatment indications
- Over 95% of patients are satisfied and willing to recommend treatment to relatives


These results further affirm the role of Phakic ICL EVO in modern refractive treatment, especially for cases of high myopia, thin corneas, or patients who are not suitable candidates for laser surgery.


In addition to other program content, doctors also focused on exchanging views on clinical indications, surgical techniques, postoperative follow-up, and technological updates related to Phakic ICL EVO, aiming to optimize long-term visual outcomes and patient safety.





Through the conference, Vietnam–Russia International Eye Hospital, Ho Chi Minh City continues to affirm its professional development orientation based on real-world data, international standards, and patient experience in modern ophthalmic care.







